Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | THRA | P10827 | 1/20 | 0.46 |
| ▸ | THRB | P10828 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.46 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2950207 | 0.84 | MCL1 (0.62) | FKBP1ANPSR1RXFP1KDM4ECARM1 | |
| SCHEMBL584257 | 0.82 | ATM (0.65) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL28255143 | 0.82 | ALDH1A1 (0.46) | FKBP1AKDM4EALDH1A1HSD17B10MAPT | |
| SCHEMBL5522283 | 0.80 | ALDH1A1 (0.55) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL8504163 | 0.78 | ALDH1A1 (0.47) | KDM4EALDH1A1HSD17B10MAPTKMT2A | |
| SCHEMBL30876366 | 0.78 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL19317367 | 0.78 | ALDH1A1 (0.53) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL24456083 | 0.77 | ALDH1A1 (0.52) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL7329831 | 0.77 | ALDH1A1 (0.52) | KDM4EALDH1A1HSD17B10MAPTATM | |
| SCHEMBL9945969 | 0.77 | KDM4E (0.58) | FKBP1AKDM4ECARM1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | FKBP1A 1546/4885NPSR1 3207/4885RXFP1 3759/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | FKBP1A 1565/4885NPSR1 3343/4885RXFP1 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.